 Innate Pharma SAs NASDAQ: IPHA data from the Phase 2 expansion cohort cohort 3 evaluating the monalizumab triplet combination shows preliminary activity and an acceptable safety profile with a low discontinuation rate. Cohort 3 is exploring the triplet combination of monalizumab, cetuximab, and durvalumab in the first-line treatment of patients with recurrent or metastatic head and neck squamous cell cancer. 